Thus, SBT-100 has demonstrated binding to KRAS, subsequently, inhibiting of KRAS GTPase activity and suppression of downstream KRAS signaling by reducing pERK levels which resulted in the inhibition of the growth of cancer cells with activating KRAS mutations. Here, KRAS is linked to cancer.